Daphne Karydas, Director at Mineralys Therapeutics, Inc. (MLYS), sold 30,000 shares at $46.36 ($1.4M) on 2025-11-13, disclosed to the SEC on 2025-11-13.
Open-market sale of $1.4M MLYS by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $45.81 | 10,115 | $463K | 33.6% |
| 2 | $45.81 | 10,115 | $463K | 33.6% |
| 3 | $46.36 | 4,885 | $226K | 16.4% |
| 4 | $46.36 | 4,885 | $226K | 16.4% |
| Total | $45.99 avg | 30,000 | $1.4M | 100% |
| Filing → |
| MLYS | SELL | 2026-04-02 | $75K | — | Filing → |